255 related articles for article (PubMed ID: 25684370)
1. The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects.
Cannon MV; Yu H; Candido WM; Dokter MM; Lindstedt EL; Silljé HH; van Gilst WH; de Boer RA
Eur J Heart Fail; 2015 Mar; 17(3):273-82. PubMed ID: 25684370
[TBL] [Abstract][Full Text] [Related]
2. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.
van der Hoorn J; Lindén D; Lindahl U; Bekkers M; Voskuilen M; Nilsson R; Oscarsson J; Lindstedt E; Princen H
Br J Pharmacol; 2011 Apr; 162(7):1553-63. PubMed ID: 21175581
[TBL] [Abstract][Full Text] [Related]
3. Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenol-Induced Cardiac Damage.
Ritter D; Goeritzer M; Thiele A; Blumrich A; Beyhoff N; Luettges K; Smeir E; Kasch J; Grune J; Müller OJ; Klopfleisch R; Jaeger C; Foryst-Ludwig A; Kintscher U
J Am Heart Assoc; 2021 Jul; 10(14):e019473. PubMed ID: 34227403
[TBL] [Abstract][Full Text] [Related]
4. Partial inhibition of activin receptor-like kinase 4 attenuates pressure overload-induced cardiac fibrosis and improves cardiac function.
Li CY; Chen YH; Wang Q; Hou JW; Wang H; Wang YP; Li YG
J Hypertens; 2016 Sep; 34(9):1766-77. PubMed ID: 27379535
[TBL] [Abstract][Full Text] [Related]
5. ADAMTS16 activates latent TGF-β, accentuating fibrosis and dysfunction of the pressure-overloaded heart.
Yao Y; Hu C; Song Q; Li Y; Da X; Yu Y; Li H; Clark IM; Chen Q; Wang QK
Cardiovasc Res; 2020 Apr; 116(5):956-969. PubMed ID: 31297506
[TBL] [Abstract][Full Text] [Related]
6. Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling.
Wu S; Yin R; Ernest R; Li Y; Zhelyabovska O; Luo J; Yang Y; Yang Q
Cardiovasc Res; 2009 Oct; 84(1):119-26. PubMed ID: 19487338
[TBL] [Abstract][Full Text] [Related]
7. Breviscapine protects against cardiac hypertrophy through blocking PKC-alpha-dependent signaling.
Yan L; Huang H; Tang QZ; Zhu LH; Wang L; Liu C; Bian ZY; Li H
J Cell Biochem; 2010 Apr; 109(6):1158-71. PubMed ID: 20127712
[TBL] [Abstract][Full Text] [Related]
8. Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC-1β: In vivo and in vitro studies.
Zhai M; Liu Z; Zhang B; Jing L; Li B; Li K; Chen X; Zhang M; Yu B; Ren K; Yang Y; Yi W; Yang J; Liu J; Yi D; Liang H; Jin Z; Reiter RJ; Duan W; Yu S
J Pineal Res; 2017 Oct; 63(3):. PubMed ID: 28708271
[TBL] [Abstract][Full Text] [Related]
9. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
Liao Y; Asakura M; Takashima S; Ogai A; Asano Y; Shintani Y; Minamino T; Asanuma H; Sanada S; Kim J; Kitamura S; Tomoike H; Hori M; Kitakaze M
Circulation; 2004 Aug; 110(6):692-9. PubMed ID: 15262839
[TBL] [Abstract][Full Text] [Related]
10. Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages.
Beyer C; Huang J; Beer J; Zhang Y; Palumbo-Zerr K; Zerr P; Distler A; Dees C; Maier C; Munoz L; Krönke G; Uderhardt S; Distler O; Jones S; Rose-John S; Oravecz T; Schett G; Distler JH
Ann Rheum Dis; 2015 Jun; 74(6):1317-24. PubMed ID: 24618263
[TBL] [Abstract][Full Text] [Related]
11. Priming with synthetic oligonucleotides attenuates pressure overload-induced inflammation and cardiac hypertrophy in mice.
Velten M; Duerr GD; Pessies T; Schild J; Lohner R; Mersmann J; Dewald O; Zacharowski K; Klaschik S; Hilbert T; Hoeft A; Baumgarten G; Meyer R; Boehm O; Knuefermann P
Cardiovasc Res; 2012 Dec; 96(3):422-32. PubMed ID: 22977006
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis.
Watson CJ; Horgan S; Neary R; Glezeva N; Tea I; Corrigan N; McDonald K; Ledwidge M; Baugh J
J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):127-37. PubMed ID: 26130616
[TBL] [Abstract][Full Text] [Related]
13. Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation.
Bugyei-Twum A; Ford C; Civitarese R; Seegobin J; Advani SL; Desjardins JF; Kabir G; Zhang Y; Mitchell M; Switzer J; Thai K; Shen V; Abadeh A; Singh KK; Billia F; Advani A; Gilbert RE; Connelly KA
Cardiovasc Res; 2018 Oct; 114(12):1629-1641. PubMed ID: 29800064
[TBL] [Abstract][Full Text] [Related]
14. Activation of Liver X receptors in the heart leads to accumulation of intracellular lipids and attenuation of ischemia-reperfusion injury.
Lei P; Baysa A; Nebb HI; Valen G; Skomedal T; Osnes JB; Yang Z; Haugen F
Basic Res Cardiol; 2013 Jan; 108(1):323. PubMed ID: 23266787
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of Nrf2/HO-1 and inhibition of TGF-β1/Smad2/3 signaling axis by daphnetin alleviates transverse aortic constriction-induced cardiac remodeling in mice.
Syed AM; Kundu S; Ram C; Kulhari U; Kumar A; Mugale MN; Mohapatra P; Murty US; Sahu BD
Free Radic Biol Med; 2022 Jun; 186():17-30. PubMed ID: 35513128
[TBL] [Abstract][Full Text] [Related]
16. The microRNA-15 family inhibits the TGFβ-pathway in the heart.
Tijsen AJ; van der Made I; van den Hoogenhof MM; Wijnen WJ; van Deel ED; de Groot NE; Alekseev S; Fluiter K; Schroen B; Goumans MJ; van der Velden J; Duncker DJ; Pinto YM; Creemers EE
Cardiovasc Res; 2014 Oct; 104(1):61-71. PubMed ID: 25103110
[TBL] [Abstract][Full Text] [Related]
17. Heat shock transcription factor 1 protects against pressure overload-induced cardiac fibrosis via Smad3.
Zhou N; Ye Y; Wang X; Ma B; Wu J; Li L; Wang L; Wang DW; Zou Y
J Mol Med (Berl); 2017 Apr; 95(4):445-460. PubMed ID: 28091697
[TBL] [Abstract][Full Text] [Related]
18. Activation of liver X receptor protects inner retinal damage induced by N-methyl-D-aspartate.
Zheng S; Yang H; Chen Z; Zheng C; Lei C; Lei B
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1168-80. PubMed ID: 25613943
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
Zhong J; Basu R; Guo D; Chow FL; Byrns S; Schuster M; Loibner H; Wang XH; Penninger JM; Kassiri Z; Oudit GY
Circulation; 2010 Aug; 122(7):717-28, 18 p following 728. PubMed ID: 20679547
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of a novel liver X receptor agonist with partial LXRα activity and a favorable window in nonhuman primates.
Kirchgessner TG; Martin R; Sleph P; Grimm D; Liu X; Lupisella J; Smalley J; Narayanan R; Xie Y; Ostrowski J; Cantor GH; Mohan R; Kick E
J Pharmacol Exp Ther; 2015 Feb; 352(2):305-14. PubMed ID: 25467132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
